Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

Over the past decade, the global process of drug discovery within the life sciences sector has shifted, becoming more open and collaborative across both disciplines and sectors. Innovations in ...